Global Blood Therapeutics, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 3 Phase 4
Founded: San Francisco CA United States (2012)

Organization Overview

First Clinical Trial
2014
NCT02285088
First Marketed Drug
2019
voxelotor (Oxbryta)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

GBT | Global Blood Therapeutics | Global Blood Therapeutics, Inc. | GLOBAL BLOOD THERAPS

Active Ingredients

Marketed Drugs (1)

voxelotor (Oxbryta) (NDA)

Drugs in Phase 4 Trials (1)

voxelotor (Oxbryta) (22 trials)

Drugs in Phase 3 Trials (1)

inclacumab (2 trials)

Drugs in Phase 1 Trials (1)

gbt021601 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 4)

Anemia, Sickle Cell (Phase 4)

Fibrosis (Phase 2)

Hypoxia (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Kidney Diseases (Phase 2)

Liver Diseases (Phase 1)

Pulmonary Fibrosis (Phase 2)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial APIs: 3